Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9671
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Branford, S. | - |
dc.contributor.author | Rudzki, Z. | - |
dc.contributor.author | Harper, A. | - |
dc.contributor.author | Grigg, A. | - |
dc.contributor.author | Taylor, K. | - |
dc.contributor.author | Durrant, S. | - |
dc.contributor.author | Arthur, C. | - |
dc.contributor.author | Browett, P. | - |
dc.contributor.author | Schwarer, A. | - |
dc.contributor.author | Ma, D. | - |
dc.contributor.author | Seymour, J. | - |
dc.contributor.author | Bradstock, K. | - |
dc.contributor.author | Joske, D. | - |
dc.contributor.author | Lynch, K. | - |
dc.contributor.author | Gathmann, I. | - |
dc.contributor.author | Hughes, T. | - |
dc.date.issued | 2003 | - |
dc.identifier.citation | Leukemia, 2003; 17(12):2401-2409 | - |
dc.identifier.issn | 0887-6924 | - |
dc.identifier.issn | 1476-5551 | - |
dc.identifier.uri | http://hdl.handle.net/2440/9671 | - |
dc.description | © 2009 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. | - |
dc.description.abstract | We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, P<0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN+AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P=0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN+AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC-treated patients and early measurements were predictive of subsequent response. | - |
dc.language.iso | en | - |
dc.publisher | Nature Publishing Group | - |
dc.source.uri | http://www.nature.com/leu/journal/v17/n12/abs/2403158a.html | - |
dc.subject | BCR-ABL | - |
dc.subject | imatinib | - |
dc.subject | interferon alfa | - |
dc.subject | quantitative PCR | - |
dc.subject | mutation | - |
dc.title | Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1038/sj.leu.2403158 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.